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Background—The results of a number of studies in pigs and mice suggest that absence of von Willebrand factor (vWF)
protects against the development of atherosclerosis. We studied whether patients with a complete deficiency of vWF
(type 3 von Willebrand disease [vWD]) develop fewer atherosclerotic vessel wall changes than healthy controls.
Methods and Results—This study included 47 individuals with type 3 vWD and 84 healthy controls. Early atherosclerotic
changes were assessed by measuring the thickness of the intima-media in the carotid and femoral arteries by B-mode
ultrasonography. Advanced atherosclerotic changes were quantified by summing the maximal thickness of atheroscle-
rotic plaques in the carotid and femoral arteries and were expressed as a plaque score. Established risk factors were
determined to adjust for possible differences between the groups. We found no substantial difference in intima-media
thickness between vWD patients and controls (adjusted difference for carotid artery 0.007 mm, 95% CI 0.022 to
0.036 mm; femoral artery 0.069 mm, 95% CI 0.056 to 0.19 mm). Similar proportions of patients and controls had
atherosclerotic plaques (19% and 17%, respectively). No difference was found in the plaque score between groups
(adjusted difference 0.22 mm, 95% CI 0.69 to 0.26). Among vWD patients, we found no effect of treatment with
vWF concentrates on intima-media thickness or plaque score.
Conclusions—The results of this study indicate that vWF does not play a substantial role in human atherogenesis.
(Circulation. 2004;109:740-744.)
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Myocardial infarction is caused by occluding arterialthrombi on top of plaques.1 Hemostasis and coagulability
therefore play an important role during the formation of occlud-
ing arterial thrombi. In the activation of the coagulation system,
2 separate processes can be distinguished: adhesion and aggre-
gation of platelets, which results in a clot of platelets (primary
hemostasis), and a cascade of activating clotting factors that
results in the formation of insoluble fibrin from fibrinogen
(secondary hemostasis). For an adequate primary hemostasis,
von Willebrand factor (vWF) is essential.2 Furthermore, vWF
stabilizes factor VIII, one of the clotting factors involved in
secondary hemostasis. A deficiency of vWF therefore results not
only in an impaired primary hemostasis but also in an impaired
secondary hemostasis.
The role of hemostasis in ischemic cardiovascular disease
is generally thought to be in the formation of occluding
arterial thrombi. In the process of arterial thrombus forma-
tion, vWF has a key role. In particular, in vessels with high
shear stress (eg, arterioles and stenosed arteries), the presence
of vWF is required for mural thrombi to be formed.3 Further-
more, increased vWF levels have been shown to be associated
with coronary artery thrombosis.4 A number of studies,
however, suggest that vWF might also play a role in the
development of atherosclerotic plaques. Less atherosclerosis
was found in pigs and mice that had a complete deficiency of
vWF.5–9
The goal of the present study was to examine whether vWF
plays a role in atherogenesis. Atherosclerotic vessel wall
changes were determined in patients with a complete defi-
ciency of vWF (ie, type 3 von Willebrand disease [vWD])
and in individuals with a normal coagulation profile.
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Methods
Study Design
We included 47 patients with type 3 severe vWD and 84 healthy
controls. Selection of the patients with severe vWD was based on the
Italian part of a registry that was started in 1984 to register all
patients with severe vWD in Europe.10 The patients were examined
at the medical centers where they were used to be treated for their
bleeding tendency (ie, the medical centers in Milan, Bologna,
Vicenza, Florence, Rome, Naples, and Bari) and were all enrolled in
the Italian National Registry of vWD.11 The controls were healthy
individuals with a similar age and gender distribution. Each patient
was asked to provide 2 healthy controls if possible (partner, friends,
neighbors, or colleagues). For those who failed to provide the
controls, healthy volunteers (colleagues, nurses, or friends) were
asked to participate instead. The selection of the healthy volunteers
was based on the distributions of age, gender, and the region of
origin of the patients. The diagnosis of severe vWD was confirmed
in all patients and was based on the original criterion of the registry
in 1984, ie, vWF:Ag below 1 U/dL, determined by an immunora-
diometric assay.10 For both groups, only individuals aged 15 years
and older were included. The Medical Ethics Committee at our
institution approved the study, and all individuals gave their in-
formed consent for participation.
Ultrasound
The intima-media thickness of the carotid and femoral artery was
measured to quantify atherosclerotic vessel wall changes. For this
purpose, an Aloka SSD 1200 ultrasound machine with a 7.5-MHz
linear transducer was used. To avoid variability caused by use of
different ultrasound machines, one machine was used and trans-
ported to the various medical centers through Italy. The carotid
arteries were scanned with the subject in supine position. On either
side, 3 frozen images (double magnified) of the intima-media
complex in the far wall of the common carotid artery and carotid
bifurcation were visualized in the longitudinal direction and recorded
on a super-VHS videotape. All images were frozen during the
R-phase of the heart cycle with an ECG triggering module that was
attached to the ultrasound machine. If carotid plaques were present in
the measurement areas of the common carotid artery or the carotid
bifurcation, the thickest plaque in each of these areas was recorded
separately. Subsequently, the left and right common femoral arteries
were scanned according to a similar procedure.
Image Analysis
At a later stage, the images that were recorded on the videotapes
were digitized in a personal computer and saved on CD-recordable
media. The images of an individual were saved under a unique
random number to ensure blindness to the subject’s identity during
the actual measurements. Measurements were performed with the
analytical software package of the Cardiovascular Measurement
System (CMS) on a personal computer.12 Images were loaded from
the CD into the CMS and were again magnified 4 times to visualize
clearly the intima-media complex in the far wall, as has been defined
by Pignoli et al.13 Measurements in the common carotid artery were
performed in the area 2 cm proximal from the bifurcation. In the
common femoral artery, measurements were performed in the area 2
cm proximal to the bifurcation of the common femoral artery into the
superficial and deep branch of the femoral artery. In all images,
intima-media thickness was measured 6 times alongside a marker
line at constant intervals and averaged. Mean intima-media thickness
in the carotid artery was calculated by averaging the measurements
of the common carotid artery and the carotid bifurcation in both sides
(average of 72 measurements). Mean intima-media thickness in the
femoral artery was based on measurements in the common femoral
artery of both sides (average of 36 measurements). When atheroscle-
rotic plaques were present in 1 or more of the measurement areas, the
maximal thickness of each of the recorded plaques was measured 3
times and averaged. Subsequently, the obtained thicknesses of all the
recorded plaques were summed, which resulted in a single plaque
score. Image acquisitions and offline measurements were all per-
formed by 1 individual (A.S.).
Measurement of Risk Factors
By a standardized questionnaire, we obtained information from the
subjects about their smoking habits and presence of cardiovascular
disease in first-degree relatives before the age of 65 years. Smoking
habits were expressed as the number of pack-years an individual had
smoked. Body fat distribution was determined by measuring the
waist-to-hip ratio. Systolic and diastolic blood pressures were deter-
mined 3 times. Fasting total cholesterol of each individual was
determined on site, after collection of blood by a finger puncture,
with a Lipotrend C device with Lipotrend test strips (Boehringer
Mannheim). Data about the treatment of patients with severe vWD
with clotting factor concentrates were obtained from the records of
the treatment centers.
Statistical Analysis
Comparison of vessel wall thickness and exposure to various risk
factors between patients with severe vWD and healthy controls was
performed by the Student t test for continuous variables and by the
2 test for discrete variables. Variables that were not normally
distributed were transformed logarithmically. The relation between
the studied variables and intima-media thickness was determined by
linear regression analysis. The regression coefficient of a continuous
variable indicates the increase or decrease of the intima-media
thickness (in millimeters) for every unit increase of the studied
variables (eg, age and blood pressure). Discrete variables (eg, family
history for cardiovascular disease or vWD status) were coded as 0 or
1 (negative0, positive1) and inserted as such into the model. The
regression coefficient of these variables indicates the difference
between the categories. In univariate regression analysis with the
systolic and diastolic blood pressures as independent variables, 12
individuals were excluded because they used antihypertensive drugs.
Multivariate regression analysis was used to adjust for differences in
exposure to the established risk factors (ie, age, smoking habits,
waist-to-hip ratio, systolic blood pressure, total cholesterol, family
history of cardiovascular disease, use of cholesterol-lowering drugs,
and use of antihypertension drugs) between the study groups. To
examine whether there is an effect of clotting factor treatment on
vessel wall thickness, we performed univariate and multivariate
regression analysis among the vWD patients with mean annual vWF
concentrate treatment as an independent variable.
Results
General characteristics and presence of established risk factors
for atherosclerosis in patients and controls are shown in Table 1.
Age and gender distribution and exposure to most of the risk
factors were similar between both groups. A larger proportion of
vWD patients used drugs to control blood pressure (difference
12%, 95% CI 1% to 24%). Hypertension (defined as either a
systolic blood pressure 140 mm Hg or a diastolic blood
pressure 90 mm Hg or use of antihypertensive drugs) was
slightly more common in vWD patients (difference 10%, 95%
CI 5% to 25%). Subdivision into grades of hypertension
according to World Health Organization guidelines indicated
that blood pressure among individuals with hypertension might
be slightly higher in patients with severe vWD than in healthy
controls (difference between patients and controls when moder-
ate and severe hypertension are taken together 5%, 95% CI
2% to 13%). Lifetime treatment with vWF concentrate among
the vWD patients ranged from 0 to 845 000 U (median 43 500
U). The mean annual treatment ranged from 0 to 18 667 U
(median 1733 U).
A crude comparison of intima-media thickness between
patients and healthy controls is shown in Figure 1 (carotid
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artery) and Figure 2 (femoral artery). For both arteries, we
found no difference between groups.
To examine the relation between vessel wall thickness in
the carotid and femoral artery and the various risk factors,
regression analysis was performed. First, univariate regres-
sion analysis was performed (Table 2). For both arteries, a
clear relation was found between vessel wall thickness and
most of the risk factors. We did not find an effect of gender
(regression coefficient for carotid artery 0.002 mm, regres-
sion coefficient for femoral artery 0.06 mm) or of the
presence of severe vWD (regression coefficient for carotid
artery 0.005 mm, regression coefficient for femoral artery
0.022 mm) with regard to either artery. Furthermore, we
found no effect of annual vWF concentrate treatment among
vWD patients (regression coefficient for carotid artery
0.007 mm, regression coefficient for femoral artery
0.015 mm). Subsequently, we performed multivariate regres-
sion analysis to adjust for the minor differences in exposure to
the established risk factors. Multivariate regression analysis
revealed no difference in intima-media thickness in the carotid
artery between patients and controls (regression coefficient
0.007 mm, 95% CI 0.022 to 0.036). For the femoral artery,
however, a minor tendency for a thicker intima-media emerged
among healthy controls compared with patients (regression
coefficient 0.069 mm, 95% CI 0.056 to 0.19). Among vWD
patients, we found no relation between annual vWF concentrate
treatment (per 1000 U) and intima-media thickness (regression
coefficient for carotid artery 0.002 mm, 95% CI 0.007 to
0.004; regression coefficient for femoral artery 0.005 mm,
95% CI 0.013 to 0.003).
To examine whether a complete deficiency of vWF protects
against the development and growth of advanced atherosclerotic
TABLE 1. General Characteristics of Patients With Type 3 VWD and Controls
Variables
VWD
(n47)
Healthy Controls
(n84) 95% CI of Difference
Age, y 35 37 6 to 3
Smoking, pack-years 9.3 8.3 0.4 to 1.2*
Waist-to-hip ratio 0.85 0.85 0.04 to 0.04
Systolic blood pressure, mm Hg 123.2 118.0 0.01 to 0.08*
Diastolic blood pressure, mm Hg 79.0 74.7 0.002 to 0.1*
Total cholesterol, mmol/L 4.6 5.0 0.8 to 0.02
Male gender, n (%) 20 (43) 32 (39) 13 to 22%
Positive family history, n (%) 5 (11) 12 (15) 15 to 8%
Use of cholesterol-lowering drugs, n (%) 1 (2) 0 (0) 2 to 6%
Use of antihypertension drugs, n (%) 8 (17) 4 (5) 1 to 24%
Hypertension (overall), n (%) 13 (28) 15 (18) 5 to 25%
Hypertension (mild), n (%) 2 (4) 10 (12) 17 to 1%
Hypertension (moderate and severe), n (%) 3 (6) 1 (1) 2 to 13%
Overall hypertension was defined as either a systolic blood pressure 140 mm Hg or a diastolic
blood pressure 90 mm Hg or use of antihypertension drugs. Mild hypertension was defined as
either a systolic blood pressure between 140 and 159 mm Hg or a diastolic blood pressure between
90 and 99 mm Hg (individuals using antihypertension drugs were excluded). Moderate and severe
hypertension was defined as either a systolic blood pressure 160 mm Hg or a diastolic blood
pressure 100 mm Hg (individuals using antihypertension drugs were excluded).
*After logarithmic transformation.
Figure 1. Comparison of mean intima-media thickness in
carotid artery between patients with severe vWD and healthy
controls.
Figure 2. Comparison of mean intima-media thickness in femo-
ral artery between patients with severe vWD and healthy
controls.
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lesions, we compared the presence of atherosclerotic plaques in the
carotid and femoral arteries between study groups. A similar
proportion of vWD patients and controls had 1 or more visible
atherosclerotic plaques in the measurement areas of the carotid and
femoral arteries (19% and 17%, respectively). Subsequently, the
thickness of the thickest plaque in every measurement area was
summed, which resulted in a plaque score that ranged from 0 to
11.3 mm. No adjusted difference in plaque score between the 2
groups was found (difference0.22 mm, 95% CI0.69 to 0.26).
Furthermore, we found no effect of annual vWF concentrate
treatment (per 1000 U) on plaque score among vWD patients
(regression coefficient 0.017 mm, 95% CI 0.107 to 0.072).
Discussion
In the present study, we examined whether a hereditary complete
deficiency of vWF results in fewer atherosclerotic vessel wall
changes. Patients with type 3 vWD have no measurable vWF
levels in plasma, platelets, and endothelial cells14 and therefore
form the ideal group to study the pathogenic role of vWF in
human atherogenesis. The results show that individuals with a
complete deficiency are not protected against the development
of early and advanced atherosclerotic lesions.
We measured intima-media thickness in the carotid and
femoral artery by B-mode ultrasonography as an indicator of
generalized and coronary atherosclerosis. Histological studies
have shown that quantification of the intima-media thickness
in the far wall of arteries by ultrasonography corresponds
well with the true histological thickness.13,15 The results of
the present study and numerous other studies showed clear
relationships between ultrasonographically determined
intima-media thickness in the carotid and femoral artery and
exposure to the established risk factors of atherosclerosis,
such as arterial hypertension and hypercholesterolemia, even
in young individuals.16–19 Furthermore, it has been shown
that intima-media thickness of the carotid and femoral artery
is a good indicator of atherosclerotic lesions in the coronary
and peripheral arteries.20–22 In a recent study, we have shown
that the technique we have used is reliable and accurate to
determine intima-media thickness in the carotid and femoral
artery.23 One might wonder, however, whether intima-media
thickness in relatively young individuals represents a true
stage in the development of atherosclerosis. Atherosclerotic
plaques (present in nearly 20% of the individuals) were
therefore also quantified and included in the analysis.
Experimental animal studies in pigs with vWD showed a
protection against aortic atherosclerosis in pigs with homozy-
gous (severe) vWD, whereas no protection was found in pigs
with heterozygous (mild) vWD.6,24 These findings are sup-
ported by the results of a recently published study in mice
with a complete deficiency of vWF.9 Because vWF plays a
role in primary and secondary hemostasis, protection against
atherosclerosis could be explained by decreased adhesion and
aggregation of platelets to endothelial and subendothelial
structures25–27 and by decreased plasmatic coagulability.28 In
a recent study, we found no substantial protection against
atherosclerosis among individuals with hemophilia.22 That
result suggests that the protection that was found in pigs and
mice with severe vWD is caused by an impaired adhesion and
aggregation of platelets to the vessel wall. Postmortem
studies of individuals who had severe vWD, however,
showed that patients with a complete deficiency of vWF
developed advanced atherosclerotic lesions.29,30
The results of the present study do not support the
protection that was found in the pigs and mice with severe
vWD and confirm previous autopsy findings in men.30 An
explanation for this difference in results might be that the
patients in the present study were treated with clotting factors
during bleeding episodes, whereas the pigs and mice were
never treated. Among the patients with severe vWD, how-
ever, we found no relation between treatment with clotting
factors and atherosclerotic vessel wall changes. Furthermore,
platelet and endothelial vWF are not modified by transfused
concentrates.14 Another explanation might be the different
arteries in which we have quantified the atherosclerotic
TABLE 2. Univariate Regression Analysis of Intima-Media Thickness in Carotid and
Femoral Artery
Carotid Artery Femoral Artery
Variables Coefficient 95% CI Coefficient 95% CI
Age (10 years) 0.075 0.06 to 0.09 0.19 0.14 to 0.24
Smoking (10 pack-years) 0.038 0.02 to 0.05 0.10 0.05 to 0.14
Waist-to-hip ratio 0.38 0.17 to 0.60 0.64 0.050 to 1.33
Systolic blood pressure (10 mm Hg) 0.026 0.01 to 0.04 0.056 0.03 to 0.08
Diastolic blood pressure (10 mm Hg) 0.029 0.01 to 0.05 0.061 0.03 to 0.10
Total cholesterol (mmol/L) 0.029 0.013 to 0.044 0.080 0.021 to 0.14
Gender (males vs females) 0.002 0.044 to 0.048 0.06 0.20 to 0.082
Positive family history 0.12 0.058 to 0.19 0.16 0.044 to 0.37
Hypertension 0.13 0.076 to 0.18 0.37 0.22 to 0.53
vWD vs controls 0.005 0.052 to 0.042 0.022 0.12 to 0.17
Annual vWF concentrate treatment (1000 U)* 0.007 0.017 to 0.004 0.015 0.032 to 0.003
Hypertension was defined as either a systolic blood pressure 140 mm Hg or a diastolic blood pressure
90 mm Hg or use of antihypertension drugs.
*Analysis among vWD patients only.
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changes. In the pigs, protection against aortic atherosclerosis
was found, whereas no protection was found in the coronary
arteries.8,24,31,32 It is known that the pace of development of
atherosclerosis is different for the various sites in the vessel
tree, depending on some recognized factors, such as shear
stress, and some as yet unknown factors.33 In the present
study, we found advanced atherosclerotic lesions and found
no differences between groups. Furthermore, we showed in a
previous study that intima-media thickness measurements in
the carotid and especially in the femoral artery are a good
indicator of advanced atherosclerotic lesions in the coronary
arteries.22 Because the major role of vWF is to promote
thrombus formation in stenosed vessels,2 we can speculate
that type 3 vWD patients, who lack vWF in plasma, platelet,
and subendothelium, might be protected against arterial
occlusion even in the presence of atherosclerotic lesions.
The data suggest a slightly higher prevalence and severity of
hypertension among patients with severe vWD. In a study that
was performed in patients with hemophilia, a higher prevalence
of hypertension was found.34 The results of the present study are
based on a relatively small number of subjects. Our results,
however, warrant a larger study on the prevalence of hyperten-
sion in patients with vWD. The results of the present study show
no protection against atherosclerosis in patients with type 3
vWD and suggest that vWF does not play a significant role in
the origin of human atherosclerosis.
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